Paternité, pas d'utilisation commerciale, partage des conditions initiales à l'identique
Langue
English
Extrait
The legally binding text is the original French version TRANSPARENCY COMMITTEE
OPINION 14 March 2012 ABILIFY 10 mg, tablet B/28 (CIP code: 364 073-4) ABILIFY 15 mg, tablet B/28 (CIP code: 364 078-6) ABILIFY 5 mg, tablet B/28 (CIP code: 364 069-7) ABILIFY 10 mg, orodispersible tablet B/28 (CIP code: 369 214-5) ABILIFY 15 mg, orodispersible tablet B/28 (CIP code: 369 217-4) Applicant: OTSUKA PHARMACEUTICAL FRANCE SAS AripiprazoleATC Code: N05AX12 List I Dates of Marketing Authorisations (centralised procedure): ABILIFY 5 mg, 10 mg, 15 mg tablet: 04/06/2004 ABILIFY 10 mg, 15 mg orodispersible tablet: 20/06/2005 Reason for request: Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code. Therapeutic indications: “ABILIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 and older. ABILIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I disorder and for the prevention of a new manic episode in patients who have experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. The transparency Commission has re-assessed oral atypical antipsychotics in the treatment of adult schizophrenia (c.f. report attached). The results of the epidemiological study (STAR study) done at the request of the Transparency Committee were taken into account as part of this re-evaluation (cf. attached report of the public health benefit group). The conclusions of the Transparency Committee were as follows: